Case Report : A Rare Cause of Retroperitoneal Fibrosis Responding to Steroids Abstract #423

Introduction: Retroperitoneal fibrosis is a rare inflammatory disease. Neuroendocrine tumors are a heterogenous group that arise from enterochromaffin cells, most commonly in the gastrointestinal tract. Their capacity to secrete hormones, five HT, tachykinins etc, are responsible for symptoms known as carcinoid syndrome. However NETS, particularly arising from the midgut, can cause fibrosis. This can result in bowel obstruction, but also cause fibrosis in the retroperitoneum, lungs and cardiac valvular fibrosis.
Aim(s): To discuss a rare case of retroperitoneal fibrosis that responded to steroids.
Materials and methods: A 39-year-old male presented with a two-month history of upper abdominal pain and a 5-year history of back pain and acute renal failure. An USS of his liver demonstrated multiple lesions. His CT scan demonstrated multiple liver metastases and a diffuse 3 cm retroperitoneal mass encasing the aorta and the right ureter at L4 causing hydronephrosis. Biopsy of a liver lesion showed a metastatic well-differentiated neuroendocrine tumor. An Octreotide scan demonstrated significant uptake in both lobes of the liver but none in the retroperitoneal mass.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Dalvinder Mandair

To read results and conclusion, please login ...

Further abstracts you may be interested in

#133 Effectiveness of transarterial embolization of liver neuroendocrine metastases
Introduction: Neuroendocrine tumors (NETs) with diffuse liver metastases have a poor prognosis and prove difficult to palliate. Somatostatin analogues and chemotherapy have been used but often are poorly tolerated and may not provide symptom relief. Transarterial Embolization (TAE) is being increasingly used to improve symptom control and reduce tumor size. We looked at the last 5-year experience of TAE in patients with hepatic metastases from neuroendocrine tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Dalvinder S Mandair
#519 Effectiveness of Transarterial Embolization in Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NETs) with liver metastases have a poor prognosis. Somatostatin analogues and chemotherapy are used with some success. Transarterial Embolization (TAE) is increasingly used to improve symptom control and reduce tumor size.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Dalvinder Mandair
#2027 Predictors of Antiproliferative Effect of Lanreotide Autogel (LA) as First-Line Therapy for Advanced Neuroendocrine Tumors (NETs)
Introduction: The antiproliferative properties of LA in GEP NETs were demonstrated in the recently published CLARINET study
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Faidon Laskaratos
#2055 Antiproliferative Effect of Above-Label Doses of Somatostatin Analogues (SSA) for the Management of Neuroendocrine Tumors (NETs)
Introduction: Escalated doses of SSA have been used for control of refractory symptoms and tumour growth
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Faidon Laskaratos
Authors: Laskaratos F, Shah R, Banks J, Smith J, ...
#2288 Predicting Resectability of Primary Tumor and Mesenteric Lumps in Patients with Small Intestine Neuroendocrine Tumors
Introduction: Vascular infiltration and mesenteric fibrosis may jeopardize resection of primary tumor (PT) and mesenteric metastatic lumps (MLs) in small-intestine neuroendocrine tumors (SI-NETs).
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Alessandra Nella Piccioli